A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Ataluren (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors PTC Therapeutics
- 12 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Jul 2016 Status changed from not yet recruiting to recruiting.
- 13 Jul 2016 New trial record